blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2329040

EP2329040 - MOLECULAR MARKERS FOR LUNG AND COLORECTAL CARCINOMAS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  17.08.2018
Database last updated on 24.08.2024
FormerThe patent has been granted
Status updated on  08.09.2017
FormerGrant of patent is intended
Status updated on  25.04.2017
FormerExamination is in progress
Status updated on  07.03.2017
FormerGrant of patent is intended
Status updated on  28.02.2017
FormerExamination is in progress
Status updated on  20.01.2017
FormerGrant of patent is intended
Status updated on  07.12.2016
Most recent event   Tooltip03.07.2020Lapse of the patent in a contracting state
New state(s): CY, MK		published on 05.08.2020  [2020/32]
Applicant(s)For all designated states
ADVPharma, Inc.
6F., No. 90, Sec. 1
Xintai 5th Rd.
Xizhi Dist.
New Taipei City 221 / TW
For all designated states
Stason Pharmaceuticals, Inc.
11 Morgan Street
Irvine, CA 92618-2005 / US
[2017/41]
Former [2011/23]For all designated states
ADVPharma, Inc.
6F, No 90, Hsin-Tai Wu Road Sec. 1, His-Chih Town
Taipei Hsien 221 / TW
For all designated states
Stason Pharmaceuticals, Inc.
11 Morgan
Irvine, CA 92618-2005 / US
Inventor(s)01 / TERNG, Harn-Jing
9F, No. 14
Lane 49
Guoguang Rd.
Banciao City, 220 / TW
02 / LEE, Woan-Jen
2F, No. 1
Lane 27
Shueiyuan St.
Yonghe City, 234 / TW
03 / CHEN, Chin-Yu
4F, No. 167
Fu 5th St.
Qidu District
Keelung City, 206 / TW
 [2016/30]
Former [2011/23]01 / TERNG, Harn-Jing
9F, No. 14 Lane 49 Guoguang Rd.
Banciao City 220 / TW
02 / LEE, Woan-Jen
2F, No. 1 Lane 27 Shueiyuan St.
Yonghe City 234 / TW
03 / CHEN, Chin-Yu
4F, No. 167 Fu 5th St. Qidu District
Keelung City 206 / TW
Representative(s)Becker Kurig & Partner Patentanwälte mbB
Bavariastraße 7
80336 München / DE
[N/P]
Former [2017/41]Becker Kurig Straus
Patentanwälte
Bavariastrasse 7
80336 München / DE
Former [2011/23]Becker Kurig Straus
Patentanwälte Bavariastrasse 7
80336 München / DE
Application number, filing date09792084.728.08.2009
[2011/23]
WO2009US55447
Priority number, dateUS20080099008P22.09.2008         Original published format: US 99008 P
[2011/23]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2010033371
Date:25.03.2010
Language:EN
[2010/12]
Type: A2 Application without search report 
No.:EP2329040
Date:08.06.2011
Language:EN
The application published by WIPO in one of the EPO official languages on 25.03.2010 takes the place of the publication of the European patent application.
[2011/23]
Type: B1 Patent specification 
No.:EP2329040
Date:11.10.2017
Language:EN
[2017/41]
Search report(s)International search report - published on:EP12.08.2010
ClassificationIPC:C12Q1/68
[2011/23]
CPC:
C12Q1/6886 (EP,US); C12Q2600/118 (EP,US); C12Q2600/158 (EP,US)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2017/41]
Former [2011/23]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  SE,  SI,  SK,  SM,  TR 
Extension statesALNot yet paid
BANot yet paid
RSNot yet paid
TitleGerman:MOLEKULARE MARKER FÜR LUNGEN- UND KOLOREKTALKARZINOME[2011/23]
English:MOLECULAR MARKERS FOR LUNG AND COLORECTAL CARCINOMAS[2011/23]
French:MARQUEURS MOLÉCULAIRES POUR LES CARCINOMES PULMONAIRES ET COLORECTAUX[2011/23]
Entry into regional phase19.01.2011National basic fee paid 
19.01.2011Designation fee(s) paid 
19.01.2011Examination fee paid 
Examination procedure19.01.2011Examination requested  [2011/23]
31.01.2011Amendment by applicant (claims and/or description)
27.06.2013Despatch of a communication from the examining division (Time limit: M04)
24.10.2013Reply to a communication from the examining division
06.10.2014Despatch of a communication from the examining division (Time limit: M04)
06.02.2015Reply to a communication from the examining division
17.06.2016Cancellation of oral proceeding that was planned for 22.06.2016
22.06.2016Date of oral proceedings (cancelled)
30.06.2016Communication of intention to grant the patent
11.10.2016Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
08.12.2016Communication of intention to grant the patent
19.01.2017Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
01.03.2017Communication of intention to grant the patent
06.03.2017Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
26.04.2017Communication of intention to grant the patent
22.08.2017Fee for grant paid
22.08.2017Fee for publishing/printing paid
22.08.2017Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  27.06.2013
Opposition(s)12.07.2018No opposition filed within time limit [2018/38]
Fees paidRenewal fee
26.08.2011Renewal fee patent year 03
31.08.2012Renewal fee patent year 04
29.08.2013Renewal fee patent year 05
19.08.2014Renewal fee patent year 06
27.07.2015Renewal fee patent year 07
01.08.2016Renewal fee patent year 08
31.08.2017Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU28.08.2009
AT11.10.2017
CY11.10.2017
CZ11.10.2017
DK11.10.2017
EE11.10.2017
ES11.10.2017
FI11.10.2017
HR11.10.2017
IT11.10.2017
LT11.10.2017
LV11.10.2017
MC11.10.2017
MK11.10.2017
NL11.10.2017
PL11.10.2017
PT11.10.2017
RO11.10.2017
SE11.10.2017
SI11.10.2017
SK11.10.2017
SM11.10.2017
TR11.10.2017
BG11.01.2018
NO11.01.2018
GR12.01.2018
IS11.02.2018
[2020/31]
Former [2020/27]HU28.08.2009
AT11.10.2017
CZ11.10.2017
DK11.10.2017
EE11.10.2017
ES11.10.2017
FI11.10.2017
HR11.10.2017
IT11.10.2017
LT11.10.2017
LV11.10.2017
MC11.10.2017
NL11.10.2017
PL11.10.2017
PT11.10.2017
RO11.10.2017
SE11.10.2017
SI11.10.2017
SK11.10.2017
SM11.10.2017
TR11.10.2017
BG11.01.2018
NO11.01.2018
GR12.01.2018
IS11.02.2018
Former [2020/16]AT11.10.2017
CZ11.10.2017
DK11.10.2017
EE11.10.2017
ES11.10.2017
FI11.10.2017
HR11.10.2017
IT11.10.2017
LT11.10.2017
LV11.10.2017
MC11.10.2017
NL11.10.2017
PL11.10.2017
RO11.10.2017
SE11.10.2017
SI11.10.2017
SK11.10.2017
SM11.10.2017
TR11.10.2017
BG11.01.2018
NO11.01.2018
GR12.01.2018
IS11.02.2018
Former [2019/15]AT11.10.2017
CZ11.10.2017
DK11.10.2017
EE11.10.2017
ES11.10.2017
FI11.10.2017
HR11.10.2017
IT11.10.2017
LT11.10.2017
LV11.10.2017
MC11.10.2017
NL11.10.2017
PL11.10.2017
RO11.10.2017
SE11.10.2017
SI11.10.2017
SK11.10.2017
SM11.10.2017
BG11.01.2018
NO11.01.2018
GR12.01.2018
IS11.02.2018
Former [2018/52]AT11.10.2017
CZ11.10.2017
DK11.10.2017
EE11.10.2017
ES11.10.2017
FI11.10.2017
HR11.10.2017
IT11.10.2017
LT11.10.2017
LV11.10.2017
NL11.10.2017
PL11.10.2017
RO11.10.2017
SE11.10.2017
SI11.10.2017
SK11.10.2017
SM11.10.2017
BG11.01.2018
NO11.01.2018
GR12.01.2018
IS11.02.2018
Former [2018/40]AT11.10.2017
CZ11.10.2017
DK11.10.2017
EE11.10.2017
ES11.10.2017
FI11.10.2017
HR11.10.2017
IT11.10.2017
LT11.10.2017
LV11.10.2017
NL11.10.2017
PL11.10.2017
RO11.10.2017
SE11.10.2017
SK11.10.2017
SM11.10.2017
BG11.01.2018
NO11.01.2018
GR12.01.2018
IS11.02.2018
Former [2018/39]AT11.10.2017
CZ11.10.2017
DK11.10.2017
EE11.10.2017
ES11.10.2017
FI11.10.2017
HR11.10.2017
IT11.10.2017
LT11.10.2017
LV11.10.2017
NL11.10.2017
PL11.10.2017
SE11.10.2017
SK11.10.2017
SM11.10.2017
BG11.01.2018
NO11.01.2018
GR12.01.2018
IS11.02.2018
Former [2018/37]AT11.10.2017
CZ11.10.2017
DK11.10.2017
EE11.10.2017
ES11.10.2017
FI11.10.2017
HR11.10.2017
LT11.10.2017
LV11.10.2017
NL11.10.2017
PL11.10.2017
SE11.10.2017
SK11.10.2017
SM11.10.2017
BG11.01.2018
NO11.01.2018
GR12.01.2018
IS11.02.2018
Former [2018/35]AT11.10.2017
CZ11.10.2017
DK11.10.2017
EE11.10.2017
ES11.10.2017
FI11.10.2017
HR11.10.2017
LT11.10.2017
LV11.10.2017
NL11.10.2017
SE11.10.2017
SK11.10.2017
BG11.01.2018
NO11.01.2018
GR12.01.2018
IS11.02.2018
Former [2018/24]AT11.10.2017
ES11.10.2017
FI11.10.2017
HR11.10.2017
LT11.10.2017
LV11.10.2017
NL11.10.2017
SE11.10.2017
BG11.01.2018
NO11.01.2018
GR12.01.2018
IS11.02.2018
Former [2018/23]AT11.10.2017
ES11.10.2017
FI11.10.2017
HR11.10.2017
LT11.10.2017
NL11.10.2017
SE11.10.2017
NO11.01.2018
GR12.01.2018
IS11.02.2018
Former [2018/22]ES11.10.2017
FI11.10.2017
LT11.10.2017
NL11.10.2017
NO11.01.2018
Former [2018/21]FI11.10.2017
LT11.10.2017
NL11.10.2017
NO11.01.2018
Former [2018/17]NL11.10.2017
Cited inInternational search[X]WO2008070616  (UNIV UTAH RES FOUND [US], et al) [X] 1-10,14-22 * claim 56, [235], [236], [244] and the whole document *;
 [X]WO2008084219  (ONCOMETHYLOME SCIENCES SA [BE], et al) [X] 1-10,14-22 * abstract, p. 1, l. 1-25, and the whole document *;
 [XI]WO2007013671  (ONCOTHERAPY SCIENCE INC [JP], et al) [X] 1-10,14-22 * abstract, [0056-0062], tab. 1-7 and the whole document, [0120]-[0123] * [I] 11,23-24,26;
 [X]WO2007071053  (UNIV MONTREAL [CA], et al) [X] 26 * [0061] *;
 [X]  - CHENG MIN ET AL, "Diagnostic utility of LunX mRNA in peripheral blood and pleural fluid in patients with primary non-small cell lung cancer", BMC CANCER, BIOMED CENTRAL, LONDON, GB, (20080531), vol. 8, no. 1, ISSN 1471-2407, page 156, XP021034589 [X] 1-10,14-22 * abstract, p. 157, col. 2, p. 160, col. 2, p. 166, col. 1 and the whole document *
 [A]  - CHEN HSUAN-YU ET AL, "A five-gene signature and clinical outcome in non-small-cell lung cancer", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, BOSTON, MA, US, (20070104), vol. 356, no. 1, ISSN 1533-4406, pages 11 - 20, XP009086044 [A] 1-11,14-24,26 * abstract, fig. 1 and the whole document *

DOI:   http://dx.doi.org/10.1056/NEJMoa060096
 [A]  - FOURNIER MARCIA V ET AL, A strategy to identify genes associated with circulating solid tumor cell survival in peripheral blood, MOLECULAR MEDICINE (NEW YORK), VOL. 5, NR. 5, PAGE(S) 313-319, (199905), ISSN 1076-1551, XP002565929 [A] 1-11,14-24,26 * abstract, fig. 3 *
 [A]  - HAMPTON REGINA ET AL, "Differential expression of carcinoembryonic antigen (CEA) splice variants in whole blood of colon cancer patients and healthy volunteers: Implication for the detection of circulating colon cancer cells", ONCOGENE, (20021107), vol. 21, no. 51, ISSN 0950-9232, pages 7817 - 7823, XP002565930 [A] 1-11,14-24,26 * abstract, p. 7817, col. 2 *

DOI:   http://dx.doi.org/10.1038/sj.onc.1205906
ExaminationWO2004048933
    - SLATTERY MARTHA L ET AL, "MAP kinase genes and colon and rectal cancer.", CARCINOGENESIS DEC 2012, (201212), vol. 33, no. 12, ISSN 1460-2180, pages 2398 - 2408
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.